Edgewood Management
IKT icon

Edgewood Management’s Inhibikase Therapeutics IKT Stock Holding History

Edgewood Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,666
Closed -$23.2K – 81
2023
Q3 		$23.2K Sell
16,666
-1
-0% -$2 ﹤0.01% 79
2023
Q2 		$60.2K Buy
+16,667
New +$62.1K ﹤0.01% 81

Other funds holding IKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Edgewood Management's IKT Position: Q4 2023 in Review

Edgewood Management sold out of Inhibikase Therapeutics (IKT) in Q4 2023, closing a stake of 16,666 shares — an estimated $23.2K sold.

Edgewood Management first reported a position in IKT in Q2 2023 and held it in 2 quarters. The position peaked at $60.2K in Q2 2023. 11 funds tracked by Wall St. Rank hold IKT as of Q4 2023.

  • Edgewood Management reported no remaining Inhibikase Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Edgewood Management sold 16,666 Inhibikase Therapeutics shares in Q4 2023, an estimated $23.2K.
  • Edgewood Management first reported a position in Inhibikase Therapeutics in Q2 2023 and held it in 2 quarters.
  • Edgewood Management's Inhibikase Therapeutics position peaked at $60.2K in Q2 2023.
  • 11 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2023.

Based on Edgewood Management's 13F filing for Q4 2023, filed 13 Feb 2024.